News

Filter

Current filters:

None

46 to 55 of 96903 results

Gilead Sciences’ Harvoni gains EU approval

Gilead Sciences’ Harvoni gains EU approval

19-11-2014

The European Commission yesterday granted marketing authorization for US biotech antiviral specialists…

Anti-viralsBiotechnologyEuropeGilead SciencesHarvoniRegulationSovaldi

Forward Pharma sues Biogen Idec over Tecfidera sales in Germany

18-11-2014

Danish biopharmaceutical company Forward Pharma has filed a law suit against US biotech major Biogen…

Biogen IdecBiotechnologyForward PharmaGermanyLegalMarkets & MarketingNeurologicalTecfidera

Stronger punishments for production and sale of fake drugs in China

18-11-2014

Chinese authorities will hand out harsher punishment for the production and sale of fake and substandard…

ChinaMarkets & MarketingPharmaceuticalProductionRegulation

Bayer/Regeneron’s Eylea approved in Japan for DME

18-11-2014

German pharma major Bayer’s Japanese subsidiary, Bayer Yakuhin, has received approval from the Ministry…

BayerBiotechnologyEyleaJapanOphthalmicsRegeneronRegulation

Medicines Australia welcomes new trade agreement with China

18-11-2014

Australia yesterday signed the Free Trade Agreement with China, after nearly 10 years of negotiations,…

AustraliaChinaFinancialMarkets & MarketingPharmaceuticalPolitics

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

18-11-2014

New data on Swiss drug major Novartis’ investigational medicine LCZ696, for patients with heart failure…

Cardio-vascularLCZ696NovartisPharmaceuticalResearchSwitzerland

Ablynx appoints ex-GSK director Johan Heylen as chief commercial officer

Ablynx appoints ex-GSK director Johan Heylen as chief commercial officer

18-11-2014

Belgian drug developer Ablynx has announced the appointment of Johan Heylen as chief commercial officer.

AblynxBelgiumBoardroomJohan HeylenPharmaceuticalVrije Universiteit Brussel

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

Merck & Co’s LDL-lowering drug Vytorin meets study endpoints

Merck & Co’s LDL-lowering drug Vytorin meets study endpoints

18-11-2014

Pharma giant Merck & Co has announced that the study investigating LDL-cholesterol-lowering drug Vytorin…

Cardio-vascularMerck & CoPharmaceuticalResearchUSAVytorinZetia

46 to 55 of 96903 results

Back to top